The Research Partnership appoints Harriet S.Kozak as US President

13th January 2010

 
The Research Partnership – the global pharma market research specialist – has recently appointed Harriet S. Kozak as US President. Based at the company’s Philadelphia office, Harriet has been tasked with developing and strengthening the business across the United States, with particular emphasis on research operations, client relations, strategic planning and product innovation.

Harriet is a well respected and highly regarded professional within the pharma research industry, boasting more than twenty-five years experience in the sector. Her background includes both agency and client side roles, and spans a range of methodologies and therapy areas, encompassing CV/Metabolic, CNS, AI/AV, Oncology and Immunology.

Harriet started her career in global research at two of the world’s most renowned pharmaceutical companies i.e. Johnson and Johnson and Bristol- Myers Squibb. She then moved agency side, firstly as a Vice President at GFK Healthcare and most recently as Vice President, Commercial Development at Adelphi International Research, where she enjoyed a five year stint.

A former President of PBIRG (Pharmaceutical Business Intelligence & Research Group), Harriet holds a BSc in Finance from Temple University and an MBA in Marketing and Finance from Philadelphia University.

Commenting on the appointment, Mary Assimakopoulos, one of the founding Directors of the Research Partnership, said: “I am thrilled to welcome Harriet to the team as she brings with her a wealth of expertise in bespoke pharma research, combined with an excellent track record for delivering actionable data and insightful consultancy.

Our US office continues to go from strength to strength and we have ambitious plans for the future, so Harriet is certainly joining us at an opportune time. As we enter our next phase of expansion, I have every confidence that her vision and fine leadership skills will ensure The Research Partnership continues to forge its place as a credible player within the US marketplace.”